JD

The Alliance of Comprehensive Planners Announces 2021 Annual Conference Agenda

Retrieved on: 
Thursday, August 12, 2021
Archuleta, News, Editorial, CFP, Journal, History, University, Society, UGA, Kahler, Book, Society of American Business Editors and Writers, Woman, Risk, Finance, Morton Margolin Prize for Distinguished Business Reporting, Psychology, ACP, NAPFA, Marriage, Atlanta Marriott Marquis, Kansas State University, Farm, National Association, Writer, Education, Program, Gerald Loeb Award, JD, List, Association, Faculty, Business, Director, Research, Kansas, Board, Phronesis, Personal, National Association of Personal Financial Advisors, Financial plan, Golden Gate University, Coaching, Pharmaceutical industry, Financial adviser

WILMINGTON, N.C., Aug. 12, 2021 /PRNewswire/ --The Alliance of Comprehensive Planners (ACP), a community of tax-focused financial planners who provide comprehensive wealth-building strategies for their clients on a commission-free retainer basis, has announced the featured speakers and agenda for their in-person conference this fall.

Key Points: 
  • WILMINGTON, N.C., Aug. 12, 2021 /PRNewswire/ --The Alliance of Comprehensive Planners (ACP), a community of tax-focused financial planners who provide comprehensive wealth-building strategies for their clients on a commission-free retainer basis, has announced the featured speakers and agenda for their in-person conference this fall.
  • The Alliance of Comprehensive Planners (ACP)is a community of tax-focused financial planners who provide comprehensive planning strategies for their clients on a commission-free retainer basis.
  • The Practical Wisdom podcast presented by the Alliance of Comprehensive Planners and hosted by ACP member Ken Robinson, CFP, JD, recently released their 19th episode of ACP advisors sharing stories of how they became successful, fee-only, comprehensive financial advisors.
  • ACP looks forward to recording another compilation episode at the upcoming 2021 conference.

NRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021

Retrieved on: 
Wednesday, August 11, 2021
COVID, National, Patient, General officer, Goal, JD, Israel Institute for Biological Research, COVID-19, United States Army, FDA, J&J, Conference, MPH, Novartis, GLOBE, Nasdaq, Private Securities Litigation Reform Act, Health, Letter, Biology, Biotechnology, International, Dark Enlightenment, US Foods, Biomedical Advanced Research and Development Authority, Human services, Webcast, Government, Food, Breakthrough therapy, ASPE, Lilly, National Security Advisor (United States), Development, Pharmaceutical industry

RADNOR, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company, today announced that management will report second quarter 2021 financial results after the market close on August 16, 2021. The company will host a conference call and webcast on August 17, 2021, 8:30 AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period. Analysts and investors interested in submitting questions must do so in advance of the call and are encouraged to email questions to the Company’s investor relations representative at [email protected].

Key Points: 
  • --Company to Host Conference Call August 17, 2021 at 8:30AM ET--
    RADNOR, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company, today announced that management will report second quarter 2021 financial results after the market close on August 16, 2021.
  • A replay will be available from the NRx Pharmaceuticals website following the call at www.nrxpharma.com .
  • NRx Pharmaceuticals (www.nrxpharma.com) (NRx) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients.
  • This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S.

Avera Health and Sema4 Announce Collaboration to Advance Precision Oncology Care

Retrieved on: 
Wednesday, August 11, 2021
Intelligence, Doctor of Pharmacy, Machine learning, Health, Molecule, LinkedIn, Patient, MBA, Avera, JD, Genomics, Data science, Oncology, Newsroom, Physician, FACS, Precision medicine, Hospital, Emerging market, YouTube, Benedictines, WES, WTS, Cancer, Genetic counseling, Medical research, Genetics, Research, Twitter, Environment, Cancer research, General manager, Thought, Neoplasm, Avera Health, History, Disease, Facebook, GLOBE, AI, Pharmaceutical industry, Medical imaging

SIOUX FALLS, S.D and STAMFORD, Conn., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Avera Health , an integrated regional health care system that serves 300 locations across the Upper Midwest, and Sema4 , a patient-centered health intelligence company, today announced a new collaboration launching a precision medicine initiative.

Key Points: 
  • SIOUX FALLS, S.D and STAMFORD, Conn., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Avera Health , an integrated regional health care system that serves 300 locations across the Upper Midwest, and Sema4 , a patient-centered health intelligence company, today announced a new collaboration launching a precision medicine initiative.
  • This collaboration will take that a step further by leveraging Centrellis, Sema4s health intelligence platform, to curate, structure and integrate clinical and genomic data to support both cancer research and clinical care at Avera Health.
  • The collaboration between Avera Health and Sema4 significantly builds upon Avera Healths existing clinical genomic offerings, led by the Molecular and Experimental Medicine team, Avera Institute for Human Genetics, the Avera Cancer Research team, and its dedicated physicians and genetic counseling clinical team.
  • Avera Health is an outstanding health system with a proven history of excellence and innovation in personalized care and research, said Michelle Zimmerman , JD, MBA, General Manager of Oncology Solutions and Emerging Markets at Sema4.

Collabra Technology Hires Industry Veteran Russ Cofano as CEO

Retrieved on: 
Wednesday, August 11, 2021
CIO, CEO, JD, BA, Partnership, Technology, MLS, Solution, Retirement, University of Washington Information School, Activated sludge, Case, Board, University, Microsoft, Move, Growth, Management

SPOKANE, Wash., Aug. 11, 2021 /PRNewswire-PRWeb/ -- Collabra Technology, Inc., a leading provider of digital marketing and collaboration solutions for the real estate industry, is pleased to announce the hiring of Russ Cofano as the company's new president and CEO, following the retirement of co-founder and CEO Janet Case.

Key Points: 
  • SPOKANE, Wash., Aug. 11, 2021 /PRNewswire-PRWeb/ -- Collabra Technology, Inc., a leading provider of digital marketing and collaboration solutions for the real estate industry, is pleased to announce the hiring of Russ Cofano as the company's new president and CEO, following the retirement of co-founder and CEO Janet Case.
  • Cofano has over 30 years of senior leadership experience in nearly all facets of the real estate industry including brokerage, technology, MLS, associations and affiliated businesses.
  • "With an impressive track record in the real estate industry and related businesses, Russ is a tremendous addition to Collabra," Case said.
  • Collabra Technology provides digital marketing technology and services under the Collabra, Collabra Media Group, TourFactory, and Proxio brands, enabling real estate agents, teams, brokerages, builders, and developers to accelerate sales through powerful digital marketing solutions.

Latham & Watkins Expands Investment Funds Practice in the Bay Area

Retrieved on: 
Tuesday, August 10, 2021
Latham & Watkins, New York University School of Law, Lawyer, JD, United Kingdom, Javad, Investment, Partnership, Kingdom, LLM, Foreign Legal Consultant, Partner (business rank), University School, Silicon, USA, View, Multimedia, University, Leadership, Watkins, University of California, Hastings College of the Law, DeHeng Law Offices, Financial services

Mostofizadeh's practice is focused on the structuring, formation, and operation of US and global venture capital funds, as well as growth equity and private equity funds.

Key Points: 
  • Mostofizadeh's practice is focused on the structuring, formation, and operation of US and global venture capital funds, as well as growth equity and private equity funds.
  • "Javad's comprehensive understanding of the venture capital funds space, combined with his technical skills and entrepreneurial mindset, will be of tremendous benefit to our clients," said Andrea Schwartzman, Global Chair of Latham's Investment Funds Practice.
  • "He is an extremely accomplished funds practitioner and we are excited to welcome him to our market-leading Investment Funds Practice."
  • Latham & Watkins works in cooperation with the Law Office of Salman M. Al-Sudairi in the Kingdom of Saudi Arabia.

Veteran IP Litigator Milton Springut Joins Moses & Singer

Retrieved on: 
Tuesday, August 10, 2021
Legal, Professional Services, Chrysler, Richemont, Columbia University, Laboratory, City college, Lawyer, City College of New York, Seton Hall University, Entertainment, Advertising, JD, Software, Electricity, Technology, Electrical engineering, Computer science, Topical steroid withdrawal, Intellectual property, International and Ibero-American Foundation for Administration and Public Policies, Environment, Bell Labs, BS, Internet, Health, Northwestern Journal of Technology and Intellectual Property, IP, Patent, LLP, Communication, Kalow, 3D printing, Public relations

“Milton is one of the most influential IP rights lawyers in the country. His ability to help companies of all sizes develop their intellectual property -- and protect those rights against misappropriation and infringement -- will be a tremendous boon to our clients,” said Elizabeth A. Corradino, Chair of the Entertainment & Media, Technology and Intellectual Property practice groups.

Key Points: 
  • Moses & Singer LLP is pleased to announce the arrival of Milton Springut as a partner in its Intellectual Property practice.
  • Springut brings more than 25 years of experience in all aspects of IP litigation, prosecution, and counseling, including numerous patent, trademark, copyright, trade secret, and computer law matters.
  • Given its established midmarket presence across multiple disciplines and industries, Moses & Singer is the perfect fit for me at the right time, said Springut.
  • Springut led his own IP boutique, Springut Law, since 2013 and was previously a name partner at Kalow & Springut from 1996.

Michigan Governor Appoints Aunalytics CMO Katie Horvath to the Michigan Women’s Commission

Retrieved on: 
Tuesday, August 10, 2021
University, National Cancer Registrars Association, Industry, BSE, Caucus, Michigan Department of Civil Rights, CEO, Commission, LinkedIn, IOE, TM, Data science, JD, National Center for Integrative Biomedical Informatics, Industrial, Technology, FLOW, University of Michigan School of Information, Notre Dame, Workforce, Center for Automotive Research, Big data, Congress, Twitter, Munson Medical Center, Board, Daybreak, Woman, Microsoft, Advisory board, Center, GLOBE, IP, Horváth, AI, Commodore, Pharmaceutical industry

SOUTH BEND, Ind., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Aunalytics , a leading data platform company delivering Insights-as-a-Service for enterprise businesses, announced that the companys Chief Marketing Officer Katie Horvath has been appointed by Michigan Governor Gretchen Whitmer to the Michigan Womens Commission .

Key Points: 
  • SOUTH BEND, Ind., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Aunalytics , a leading data platform company delivering Insights-as-a-Service for enterprise businesses, announced that the companys Chief Marketing Officer Katie Horvath has been appointed by Michigan Governor Gretchen Whitmer to the Michigan Womens Commission .
  • The 15-member Michigan Women's Commission is responsible for reviewing the status of women in Michigan, directing attention to critical problems confronting women, and recognizing women's accomplishments and contributions to the state.
  • It is an honor to have been chosen to serve on the Michigan Womens Commission, which plays an instrumental role in helping women thrive in our state, said Horvath.
  • Horvath joined Aunalytics when Naveego, the data integration platform company that she led as President and CEO was acquired by Aunalytics.

MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors

Retrieved on: 
Tuesday, August 10, 2021
Arthropathy, Patient, Director, AFID, Cytokine, Stanford University, Skin, Moonlake, Ankylosing spondylitis, Human biology, Biotechnology, Hidradenitis suppurativa, JD, Sale, Boehringer Ingelheim, Biology, Merck Group, Board, Company, BVF, Merck, Harvard Law School, Single-domain antibody, Pharmaceutical industry

Previously, Mr. Sturge served as Chief Operating Officer for Merck Healthcare, a division of Merck KGaA.

Key Points: 
  • Previously, Mr. Sturge served as Chief Operating Officer for Merck Healthcare, a division of Merck KGaA.
  • It is a privilege to support a first-class leadership team of immunology specialists in my role as Chairman.
  • MoonLake also announced that Spike Loy, Managing Director of BVF Partners L.P. ("BVF") has been appointed a Member of the Board of Directors.
  • I am excited to support the expert team at MoonLake in my role as Board member and investor."

MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors

Retrieved on: 
Tuesday, August 10, 2021
Arthropathy, Patient, Director, AFID, Cytokine, Stanford University, Skin, Moonlake, Ankylosing spondylitis, Human biology, Biotechnology, Hidradenitis suppurativa, JD, Sale, Boehringer Ingelheim, Biology, Merck Group, Board, Company, BVF, Merck, Harvard Law School, Single-domain antibody, CEO, Pharmaceutical industry

ZUG, Switzerland, Aug. 10, 2021 /PRNewswire/ -- MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the appointment of Mr. Sturge as Chairman. He has 40 years of international leadership experience in the biotechnology and pharmaceutical industry. Most recently, he was Chief Executive Officer of Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immunologic disease and immune-oncology, and was instrumental in its sale to Sanofi in early 2021. Previously, Mr. Sturge served as Chief Operating Officer for Merck Healthcare, a division of Merck KGaA. He has also held roles at Boehringer Ingelheim, Celltech Biologics and Ribotargets.

Key Points: 
  • Previously, Mr. Sturge served as Chief Operating Officer for Merck Healthcare, a division of Merck KGaA.
  • It is a privilege to support a first-class leadership team of immunology specialists in my role as Chairman.
  • MoonLake also announced that Spike Loy, Managing Director of BVF Partners L.P. ("BVF") has been appointed a Member of the Board of Directors.
  • I am excited to support the expert team at MoonLake in my role as Board member and investor."

Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 10, 2021
Autism, Private Securities Litigation Reform Act, Clostridioides difficile infection, Patient, Food, Patent, COVID-19, Research, Inflammatory bowel disease, Public expenditure, GI, Marketing, FNCH, Hepatitis, HBeAg, U.S. Securities and Exchange Commission, Recurrence, HBV, Continuous Progress Mathematics, KOL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Breakthrough therapy, Leadership, Biomarker, DO, Growth, SEC, Drug Safety, JD, MPH, GLOBE, Therapy, IBD, Partnership, IRB, DNA, Board, Ulcerative colitis, ASD, CDI, Board of directors, Doctor of Philosophy, Security (finance), Medicine, Pharmaceutical industry

Continued progress advancing development programs, with clinical data across multiple programs anticipated in 2022

Key Points: 
  • Continued progress advancing development programs, with clinical data across multiple programs anticipated in 2022
    SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.
  • Finch reported a net loss of $15.2 million for the second quarter of 2021 as compared to a net loss of $8.3 million for the same period in 2020.
  • Research and development expenses for the second quarter of 2021 were $14.0 million, compared with $8.1 million for the same period in 2020.
  • Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discoveryplatform to develop a novel class of orally administered biological drugs.